January 2022

BANDIT trial filled

Thanks to the generosity of the type 1 diabetes community, we have completed recruitment for the BANDIT trial.


December 2023

Research breakthrough

In a world-first, ATIC researchers lead by Professor’s Thomas Kay and Helen Thomas have shown that baricitinib, an immunotherapy treatment commonly used in rheumatoid arthritis, can delay the progression of type 1 diabetes...


Page last updated: 21 November 2023